Exhibit 99


                                  James H. Miller
                                  Chairman, President 
                                  and CEO
                                     and
                                  Jeffrey W. Church
                                  Sr. Vice President
                                  Finance and CFO
                                  1-800-638-8093

FOR IMMEDIATE RELEASE

      STI AND BRUNSWICK BIOMEDICAL AGREE TO MERGE

ROCKVILLE, Maryland, September 11, 1996--Survival 
Technology, Inc. (STI) (NASDAQ:STIQ) today announced it 
has signed an agreement to merge with Brunswick 
Biomedical Corporation, a privately-held medical device 
company and holder of 61 percent of STI's stock, with 
STI as the surviving entity.

Pursuant to the agreement, each of Brunswick's 
outstanding shares of common stock will be converted 
into a right to receive 2.1 shares of STI's common 
stock.  Each of Brunswick's outstanding shares of 
preferred stock will be converted into a right to 
receive 2.1 shares of STI's common stock and a warrant 
to purchase 0.4 share of STI's common stock at an 
exercise price of $11.00 per share, exercisable for a 
period of five years following the merger.  In addition, 
STI will assume Brunswick's obligations under 
outstanding options and warrants.  These provisions of 
the agreement will result in approximately 1.7 million 
shares of STI common stock being issued in exchange for 
the Brunswick stock at the time of the merger and may 
result in the issuance of an additional approximately 1.05 million 
shares of STI common stock if all options and warrants 
were exercised and the required consideration paid.  
Each of the 1,888,126 shares of STI common stock 
currently owned by Brunswick will be retired in the 
merger.

The transaction is subject to the approval of both STI's 
and Brunswick's shareholders.  It is anticipated that 
the transaction will be accounted for by the purchase 
method of accounting and will be completed this fall.




                                  - 6 -




Brunswick acquired the 61 percent block from the estate 
of STI's late founder, Dr. Stanley J. Sarnoff, in April 
1996.  The signing of the merger agreement culminates a 
three-month process of negotiation conducted by a 
special committee of STI independent directors with the 
assistance of Lehman Brothers.

"Combining STI and Brunswick creates a new medical 
device company well-positioned to take advantage of the 
substantial growth opportunity in the rapidly expanding 
medical device industry," said James H. Miller, 
chairman, president and chief executive officer of STI.  
"We believe that the combination will significantly 
increase the liquidity of our stock, thus enhancing the 
opportunity for a broader trading market and the 
company's access to capital markets."

Brunswick manufactures the CardioBeeper-Registered Trademark-  
personal heart monitor, co-developed with STI to transmit
heart function data to medical centers by telephone, and other 
telemedicine devices.  In addition, a 64-lead cardiac 
mapping system (PRIME ECG -TM-) to aid in the rapid 
diagnosis of cardiac ischemia, was recently launched in 
Europe and an educational CD-ROM product will be 
launched shortly.

STI is the worldwide leader in auto-injector technology.  
An original development of STI, auto-injectors are 
spring-loaded, prefilled devices that allow patients to 
self-administer precise doses of injectable medication 
quickly, safely, easily and without the apprehension 
associated with a traditional syringe.  The company 
currently produces auto-injectors used in the emergency 
treatment of allergic reactions and irregular 
heartbeats, and by military personnel for 
self-administration of nerve gas antidotes, morphine and 
diazapam.

STI also supplies customized drug delivery system 
design, pharmaceutical research and development, and 
sterile product manufacturing to pharmaceutical and 
biotechnology companies.  The company's products and 
services are designed to improve the medical and 
economic value of drug therapy.









                                  - 7 -